February 1, 2018 / 10:32 AM / a year ago

BRIEF-Novo Nordisk To Initiate Cardiovascular Outcomes Study With Diabetes Drug Ozempic in 2018

Feb 1 (Reuters) - NOVO NORDISK’S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN SAYS:

* LARGE CV OUTCOMES STUDY TO BE INITIATED MID-2018 WITH DIABETES DRUG OZEMPIC; RESULTS DUE AROUND 2023

* THE STUDY WILL INCLUDE 13,000 PATIENTS FURTHER COMPANY COVERAGE: (Reporting by Jacob Grønholt-Pedersen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below